Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that makes it increasingly difficult to breathe. It is the fourth leading cause of death in the United States and a major cause of chronic disability worldwide. COPD is characterized by persistent airflow limitation and encompasses two main conditions: emphysema, in which the air sacs (alveoli) are damaged and lose their elasticity, and chronic bronchitis, characterized by chronic inflammation and excessive mucus production in the airways. Cigarette smoking is by far the most significant risk factor for COPD, responsible for approximately 85–90% of cases. Long-term exposure to air pollutants, occupational dusts and chemicals, and indoor cooking or heating fumes (particularly in developing countries) also contribute. A rare genetic condition called alpha-1 antitrypsin deficiency can cause COPD even in non-smokers. Symptoms of COPD develop slowly and worsen over time. Early signs include a chronic cough (often dismissed as a "smoker's cough"), increased mucus production, and mild shortness of breath on exertion. As the disease progresses, breathlessness becomes more severe, occurring with minimal activity or at rest. Patients also experience reduced exercise tolerance, recurrent respiratory infections (exacerbations), and significant fatigue. Diagnosis is confirmed by spirometry, which measures the degree of airflow limitation. The GOLD staging system classifies COPD into four severity grades. Management focuses on slowing disease progression, relieving symptoms, and preventing exacerbations. Smoking cessation is the single most important intervention. Bronchodilators (short- and long-acting beta-agonists and anticholinergics) are the cornerstone of pharmacological therapy. Inhaled corticosteroids are used in combination with long-acting bronchodilators for more severe disease. Pulmonary rehabilitation — a structured program of exercise training, education, and behavioral change — significantly improves exercise tolerance and quality of life. Supplemental oxygen is prescribed for patients with severe hypoxemia. Surgical options, including lung volume reduction surgery and lung transplantation, are available for select patients with advanced disease. Our pulmonology team at Silvaris provides comprehensive COPD management and pulmonary rehabilitation programs.
